UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2019

DARÉ BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-36395**	**20-4139823**
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

3655 Nobel Drive, Suite 260
San Diego, CA 92122
(Address of Principal Executive Offices and Zip Code)

Registrant's telephone number, including area code: **(858) 926-7655**

Not Applicable
(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	**DARE**	**Nasdaq Capital Market**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2019, Daré Bioscience, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2019. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information under this Item 2.02 and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release dated August 14, 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DARÉ BIOSCIENCE, INC.

Date: August 14, 2019

By: /s/ Sabrina Martucci Johnson
Name: Sabrina Martucci Johnson
Title: Chief Executive Officer

Daré Bioscience Reports Second Quarter 2019 Financial Results and Company Update

SAN DIEGO, August 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the second quarter ended June 30, 2019 and provided a Company update.

"Daré made tremendous progress during the second quarter and remains on track to announce meaningful milestones during the remainder of 2019 and 2020," said Sabrina Martucci Johnson, President and CEO of Daré. "In June, we were pleased to announce the completion of enrollment for the Ovaprene postcoital test clinical trial, an important milestone in the development of this potential first-in-category, hormone-free contraceptive candidate. As we enter the second half of the year, we believe we are well positioned to deliver value across our entire portfolio of clinical-stage product candidates, including reporting topline data for the Ovaprene postcoital test clinical trial and initiating the Phase 3 study for DARE-BV1 in the fourth quarter of 2019, and continuing to advance the Sildenafil Cream, 3.6% program for Female Sexual Arousal Disorder."

Quarter Ended June 30, 2019 Financial Results

- Cash and cash equivalents:
    - As of June 30, 2019, cash and cash equivalents were approximately $5.6 million, including the $5.2 million of net proceeds the Company raised from the underwritten offering it completed in April 2019.
    - In March 2019, the Company received a Notice of Award for an additional $982,851 of the anticipated $1.9 million grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. During the second quarter, the Company continued its activities under the Ovaprene postcoital test clinical trial and to use the grant to offset certain study expenses. As of June 30, 2019, the Company recorded a receivable of $456,484 for expenses eligible for reimbursement under the grant that were incurred through June 30th.
- General and administrative expenses were $1.3 million for the second quarter of 2019, as compared to $1.2 million for the same period in 2018. During the second quarter of 2019, an increase in personnel costs due to staff additions was partially offset by a decrease in expenses related to outside professional services.
- Research and development expenses were $2.5 million for the second quarter of 2019, as compared to $2.2 million for the same period in 2018. The increase reflects development activities of approximately $518,000 for two ongoing studies-- the postcoital test clinical trial of Ovaprene and the content validity study of Sildenafil Cream, 3.6%-- and to a lesser extent, activities to prepare for the clinical trials of DARE-BV1 (Phase 3) and DARE-HRT1 (Phase 1) that the Company expects to initiate later this year. The research and development expenses related to Ovaprene were partially offset by grant funding of approximately $456,000. During the second quarter of 2019, an increase in employees led to an increase in personnel costs of $233,000 as compared with the same period in 2018.

- The Company reported a comprehensive loss of $4.7 million for the second quarter of 2019, as compared to a loss of $3.6 million for the same period in 2018. The loss incurred during the second quarter of 2019 included a non-cash deemed dividend of approximately $790,000 in light of a reset in the exercise price of certain outstanding warrants.

Conference Call

Daré will host a conference call and live webcast today at 4:30 p.m. Eastern Time to review the Company's financial results for the quarter ended June 30, 2019 and to provide a Company update.

To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for the call is 2679339. The live webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 2679339. The call and webcast replay will be available until August 21, 2019.

About Daré Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. The company's mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.

Daré's product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. To learn more about Daré's full portfolio of women's health product candidates, and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website (https://darebioscience.gcs-web.com/) and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of the company's website mentioned above.

Forward Looking Statements

Daré cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," project," "target," "tend to," or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Daré's ability to announce meaningful milestones during the remainder of 2019 and 2020, and to deliver value across its entire portfolio of clinical-stage product candidates, including the timing of reporting topline data for the Ovaprene postcoital test clinical trial and the timing of initiating the Phase 3 study for DARE-BV1. Forward-looking statements

involve known and unknown risks, uncertainties and other factors that may cause Daré's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risk and uncertainties related to: Daré's ability to continue as a going concern; Daré's ability to raise additional capital when and as needed, to advance its product candidates; Daré's ability to develop, obtain regulatory approval for, and commercialize its product candidates; the failure or delay in starting, conducting and completing clinical trials or obtaining FDA or foreign regulatory approval for Daré's product candidates in a timely manner; Daré's ability to conduct and design successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Daré's ability to retain its licensed rights to develop and commercialize a product candidate; Daré's ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product candidates; developments by Daré's competitors that make its product candidates less competitive or obsolete; Daré's dependence on third parties to conduct clinical trials and manufacture clinical trial material; Daré's ability to adequately protect or enforce its, or its licensor's, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré's product candidates which could expose its products to competition from other formulations using the same active ingredients; the risk of failure associated with product candidates in preclinical stages of development that may lead investors to assign them little to no value and make these assets difficult to fund; and disputes or other developments concerning Daré's intellectual property rights. Daré's forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré's risks and uncertainties, you are encouraged to review its documents filed with the SEC including Daré's recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contacts:

Investors on behalf of Daré Bioscience, Inc.:
Lee Roth
Burns McClellan
lroth@burnsmc.com
212.213.0006

OR

Media on behalf of Daré Bioscience, Inc.:
Jake Robison
Canale Communications
jake@canalecomm.com
619.849.5383

Source: Daré Bioscience

_____.

Daré Bioscience, Inc. and Subsidiaries

Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2019	2018	2019	2018
Operating expenses:				
General and administrative	$ 1,307,379	$ 1,157,174	$ 2,584,559	$ 2,460,363
Research and development expenses	2,512,572	2,217,622	4,205,963	3,304,275
License expenses	162,500	250,000	275,000	350,000
Impairment of goodwill	-	-	-	5,187,519
Total operating expenses	3,982,451	3,624,796	7,065,522	11,302,157
Loss from operations	(3,982,451)	(3,624,796)	(7,065,522)	(11,302,157)
Other income (expense)	30,001	42,626	61,232	54,370
Net loss	$ (3,952,450)	$ (3,582,170)	$ (7,004,290)	$ (11,247,787)
Deemed dividend from trigger of down round provision feature	$ (789,594)	$ -	$ (789,594)	$ -
Net loss to common shareholders	$ (4,742,044)	$ (3,582,170)	$ (7,793,884)	$ (11,247,787)
Foreign currency translation adjustments	$ (7,917)	$ (27,485)	$ (296)	$ (41,231)
Comprehensive loss	$ (4,749,961)	$ (3,609,655)	$ (7,794,180)	$ (11,289,018)
Loss per common share - basic and diluted	$ (0.29)	$ (0.32)	$ (0.57)	$ (1.13)
Weighted average number of common shares outstanding:				
Basic and diluted	16,105,252	11,422,161	13,776,643	10,031,249

Daré Bioscience, Inc. and Subsidiaries
Consolidated Balance Sheets

	June 30, 2019 (unaudited)	December 31, 2018
Cash and cash equivalents	$ 5,630,569	$ 6,805,889
Working capital	$ 4,587,617	$ 6,148,967
Total assets	$ 7,260,932	$ 7,827,387
Total stockholders' equity	$ 5,083,055	$ 6,726,620